Education
About Us
Working with TipRanks
Follow Us
Tourmaline Bio (TRML)
NASDAQ:TRML
Total Valuation
Tourmaline Bio has a market cap or net worth of $575.25M. The enterprise value is $141.67M.
Market Cap$575.25M
Enterprise Value$141.67M
Share Statistics
Tourmaline Bio has 25,692,268 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding25,692,268
Owned by Insiders7.80%
Owned by Institutions61.50%
Financial Efficiency
Tourmaline Bio’s return on equity (ROE) is -0.24 and return on invested capital (ROIC) is -29.86%.
Return on Equity (ROE)-0.24
Return on Assets (ROA)-0.24
Return on Invested Capital (ROIC)-29.86%
Return on Capital Employed (ROCE)-0.30
Revenue Per Employee0.00
Profits Per Employee-989.32K
Employee Count74
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Tourmaline Bio is ―. Tourmaline Bio’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value1.71
Price to FCF―
Price to Operating Cash Flow-6.73
PEG Ratio―
Income Statement
In the last 12 months, Tourmaline Bio had revenue of 0.00 and earned -73.21M in profits. Earnings per share was -2.89.
Revenue0.00
Gross Profit-39.00K
Operating Income-89.73M
Pretax Income-73.21M
Net Income-73.21M
EBITDA-89.73M
Earnings Per Share (EPS)-2.89
Cash Flow
In the last 12 months, operating cash flow was -86.28M and capital expenditures -25.00K, giving a free cash flow of -86.30M billion.
Operating Cash Flow-86.28M
Free Cash Flow-86.30M
Free Cash Flow per Share-3.36
Dividends & Yields
Tourmaline Bio pays an annual dividend of $15.118, resulting in a dividend yield of ―
Dividend Per Share$15.118
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.56
52-Week Price Change61.68%
50-Day Moving Average19.13
200-Day Moving Average18.57
Relative Strength Index (RSI)64.66
Average Volume (3m)181.68K
Important Dates
Tourmaline Bio upcoming earnings date is Nov 6, 2025, Before Open (Confirmed).
Last Earnings DateAug 13, 2025
Next Earnings DateNov 6, 2025
Ex-Dividend DateOct 20, 2023
Financial Position
Tourmaline Bio as a current ratio of 30.18, with Debt / Equity ratio of 0.06%
Current Ratio30.18
Quick Ratio30.18
Debt to Market Cap<0.01
Net Debt to EBITDA0.34
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Tourmaline Bio has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Tourmaline Bio EV to EBITDA ratio is -5.39, with an EV/FCF ratio of -6.26.
EV to Sales0.00
EV to EBITDA-5.39
EV to Free Cash Flow-6.26
EV to Operating Cash Flow-6.26
Balance Sheet
Tourmaline Bio has $239.23M in cash and marketable securities with $145.00K in debt, giving a net cash position of -$239.09M billion.
Cash & Marketable Securities$239.23M
Total Debt$145.00K
Net Cash-$239.09M
Net Cash Per Share-$9.31
Tangible Book Value Per Share$11.84
Margins
Gross margin is -5.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-5.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Tourmaline Bio is $52.40, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$52.40
Price Target Upside132.17% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast6.66%